News | November 29, 2022
Fredun Pharmaceuticals signs two large contracts
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
The company sees the business reaching $100mn
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Subscribe To Our Newsletter & Stay Updated
